This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...
CRA Life Sciences experts Tim Wilsdon, Michele Pistollato, Antun Sablek, and Qinyi Wang contributed to a research article
Annabelle Fowler presents the CRA paper titled “An Analysis of Medicaid CPI Rebates and the Sustainability of U.S. Generic Markets.” Ashutosh Mishra presents...
Ryan Lawlor presents the session titled “Prioritising Alzheimer’s Disease in Europe: Next steps for Policy Action.” Tim Wilsdon moderates the panel discussion...
